GENMAB A / S (Nasdaq: Gmab) said on Monday that Johnson & Johnson (J & J) had decided not to exercise his option to obtain a global license for the development, manufacture and marketing of Hexabody-CD38.
Despite the initial clinical data showing efficiency, Genmab decided
